![conference banner](/images/conference-banner.jpeg)
Abstract
A curative therapy for HIV-1 infection will have to include measures to eliminate the reservoir of latently HIV- 1 infected cells that allow the virus to persist despite otherwise successful therapy. To date, all efforts to deplete the latent reservoir by triggering viral reactivation have used preexisting drugs that are believed to potentially target molecular mechanisms controlling HIV-1 infection. These therapeutic attempts were not clinically successful. Only in the last few years have cellular models of latent HIV-1 infection suitable for high throughput screening been developed and concerted drug discovery efforts were initiated to discover new HIV-1 reactivating drugs. We here provide a historic overview about the development of cell models with latent HIV-1 infection that lend themselves to drug discovery. We provide an overview from the first reported latently infected cell lines to current in vitro models of latent HIV-1 infection in primary T cells, and compare their potential to be used in future large-scale drug screening efforts.
Keywords: HIV-1 latency, drug screening, cytokine storm, LTR, chromatin structures, J-LAT, FK506, GFP-positive cells, screening effort
Current HIV Research
Title: Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs
Volume: 9 Issue: 8
Author(s): Olaf Kutsch, Frank Wolschendorf and Vicente Planelles
Affiliation:
Keywords: HIV-1 latency, drug screening, cytokine storm, LTR, chromatin structures, J-LAT, FK506, GFP-positive cells, screening effort
Abstract: A curative therapy for HIV-1 infection will have to include measures to eliminate the reservoir of latently HIV- 1 infected cells that allow the virus to persist despite otherwise successful therapy. To date, all efforts to deplete the latent reservoir by triggering viral reactivation have used preexisting drugs that are believed to potentially target molecular mechanisms controlling HIV-1 infection. These therapeutic attempts were not clinically successful. Only in the last few years have cellular models of latent HIV-1 infection suitable for high throughput screening been developed and concerted drug discovery efforts were initiated to discover new HIV-1 reactivating drugs. We here provide a historic overview about the development of cell models with latent HIV-1 infection that lend themselves to drug discovery. We provide an overview from the first reported latently infected cell lines to current in vitro models of latent HIV-1 infection in primary T cells, and compare their potential to be used in future large-scale drug screening efforts.
Export Options
About this article
Cite this article as:
Kutsch Olaf, Wolschendorf Frank and Planelles Vicente, Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998826
DOI https://dx.doi.org/10.2174/157016211798998826 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Screening of Some Novel 4, 5 Disubstituted 1, 2, 4-Triazole-3-thiones for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Role of Ectonucleotidases in Synapse Formation During Brain Development: Physiological and Pathological Implications
Current Neuropharmacology Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Imaging Biomarkers of Anti-Epileptic Drug Action: Insights from Magnetic Resonance Imaging
Current Pharmaceutical Design Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder
Current Medicinal Chemistry Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer’s Disease Therapy: Advances in Chemical and Biological Research
Current Medicinal Chemistry Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Genus <i>Gelsemium</i> and its Endophytic Fungi - Comprehensive Review of their Traditional Uses, Phytochemistry, Pharmacology, and Toxicology
Current Topics in Medicinal Chemistry Advancement in Epilepsy Pharmacotherapy: An Insight into the Pharmacophoric Approaches of Recent Drugs
Central Nervous System Agents in Medicinal Chemistry Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry The Emerging Role of COX-2, 15-LOX and PPARγ in Metabolic Diseases and Cancer: An Introduction to Novel Multi-target Directed Ligands (MTDLs)
Current Medicinal Chemistry Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action
Current Pharmaceutical Design Receptor to Glutamate NMDA-Type: The Functional Diversity of the NR1 Isoforms and Pharmacological Properties
Current Pharmaceutical Design The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Voxel-Based Morphometry of the Human Brain: Methods and Applications
Current Medical Imaging Patient Involvement and Shared Decision-Making in Mental Health Care
Current Clinical Pharmacology Molecular and Biochemical Features in Alzheimers Disease
Current Pharmaceutical Design Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design